Figure 5

The prevalence of resistance associated variants to IFN-free regimens in total

(A) and among various genotypes (B). GT, genotype; SMV, Simeprevir; SOF, Sofosbuvir; DCV, Daclatasvir; LDV, Ledipasvir; 3D, Paritaprevir and Ombitasvir plus Dasabuvir.